Oncopeptides AB (OSTO:ONCO) Net Margin % : -1,521.66% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Oncopeptides AB's Net Income for the three months ended in Dec. 2023 was kr-81.21 Mil. Oncopeptides AB's Revenue for the three months ended in Dec. 2023 was kr5.34 Mil. Therefore, Oncopeptides AB's net margin for the quarter that ended in Dec. 2023 was -1,521.66%.

The historical rank and industry rank for Oncopeptides AB's Net Margin % or its related term are showing as below:

OSTO:ONCO' s Net Margin % Range Over the Past 10 Years
Min: -4044.9 Med: -1209.11 Max: -707.3
Current: -707.3

OSTO:ONCO's Net Margin % is ranked worse than
69.04% of 1027 companies
in the Biotechnology industry
Industry Median: -160.92 vs OSTO:ONCO: -707.30

Oncopeptides AB Net Margin % Historical Data

The historical data trend for Oncopeptides AB's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Net Margin % Chart

Oncopeptides AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-1,209.11

-4,044.90

-707.30

Oncopeptides AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %	Get a 7-Day Free Trial															-16,267.50	-6,318.95	-217.05	-1,445.38	-1,521.66

Competitive Comparison of Oncopeptides AB's Net Margin %

For the Biotechnology subindustry, Oncopeptides AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncopeptides AB's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Net Margin % distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's Net Margin % falls into.

Oncopeptides AB Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Oncopeptides AB's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-249.111	/	35.22
	=	-707.30 %

Oncopeptides AB's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-81.211	/	5.337
	=	-1,521.66 %

Oncopeptides AB (OSTO:ONCO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Oncopeptides AB Net Margin % Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB (OSTO:ONCO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (OSTO:ONCO) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

0RN4:UK OND:Germany

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate melflufen (Ygalo), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.